Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Aims To Tap Sentinel Data Network For Drug Effectiveness Studies

Executive Summary

New ‘Guardian’ program to monitor post-market effectiveness through the Sentinel electronic data network will take five years to build, FDA’s Woodcock says.

You may also be interested in...



Sentinel May Expand To Generic Equivalence Studies

Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.

Sentinel May Expand To Generic Equivalence Studies

Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.

PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources

Growth of post-market surveillance system also may require more resources.

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel